Rana Stoops
Psychiatric/Mental Health · Anderson, INNPI 1134775463
Payments from drug & device makers
Across 65 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$762
- Johnson & Johnson$228
- Neurocrine Biosciences, Inc.$111
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$104
- Otsuka America Pharmaceutical, Inc.$98
- AbbVie$71
- plus $157 from 6 others
What the payments were for
- Food & beverage$1,48597%
- Education$473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 29 | $762 |
| Johnson & Johnson | 5 | $228 |
| Neurocrine Biosciences, Inc. | 6 | $111 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $104 |
| Otsuka America Pharmaceutical, Inc. | 6 | $98 |
| AbbVie | 5 | $71 |
| Indivior Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Corium, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$899
- SPRAVATO$131
- LYBALVI$118
- ARISTADA INITIO$107
How this compares
$1,532 in reported general payments places this provider in the 65th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 171 | $603,726 |
| Invega TrinzaPaliperidone Palmitate | 12 | $117,600 |
| Abilify MaintenaAripiprazole | 41 | $108,250 |
| RexultiBrexpiprazole | 63 | $106,254 |
| VraylarCariprazine Hcl | 29 | $60,868 |
| PerserisRisperidone | 11 | $27,160 |
| Clozapine | 282 | $20,345 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,347 |
| CaplytaLumateperone Tosylate | 11 | $17,930 |
| Zyprexa RelprevvOlanzapine Pamoate | 20 | $16,819 |
| TrintellixVortioxetine Hydrobromide | 29 | $16,149 |
| Lurasidone Hcl | 30 | $13,839 |
| Paliperidone ErPaliperidone | 49 | $12,358 |
| Oxtellar XrOxcarbazepine | 18 | $11,922 |
| Atomoxetine Hcl | 56 | $10,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $228 | $721,326183 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $98 | $214,504104 claims |
| AbbVieVraylar | $71 | $60,86829 claims |
| Indivior Inc.Perseris | $37 | $27,16011 claims |
| Alkermes, Inc.Lybalvi | $762 | $18,34712 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $104 | $17,93011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $22 | $16,14929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Anderson
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.